Articles by Bogdana Schmidt, MD, MPH

FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
ByMark D. Tyson, II, MD, MPH,Bogdana Schmidt, MD, MPH,Sam S. Chang, MD, MBA,Aaron Berger, MD Panelists discuss how recently FDA-approved therapies, including nadofaragene firadenovec, gemcitabine, and docetaxel, offer alternative treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), each with distinct mechanisms and administration methods.

Non–Muscle Invasive-Bladder Cancer Overview
ByAshish Kamat, MD, MBBS ,Sam S. Chang, MD, MBA,Bogdana Schmidt, MD, MPH,Katie S. Murray, DO, MS Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) is staged, graded, and treated according to risk stratification, with detailed explanations of low-, intermediate-, and high-risk categories and corresponding treatment pathways.

NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
ByMark D. Tyson, II, MD, MPH,Bogdana Schmidt, MD, MPH,Sam S. Chang, MD, MBA,Aaron Berger, MD Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual risk and tolerance.

Defining and Managing BCG-Unresponsive NMIBC
ByMark D. Tyson, II, MD, MPH,Bogdana Schmidt, MD, MPH,Sam S. Chang, MD, MBA,Aaron Berger, MD Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to alternative treatments.

From Papillary to CIS: Tailoring NMIBC Treatment
ByMark D. Tyson, II, MD, MPH,Bogdana Schmidt, MD, MPH,Sam S. Chang, MD, MBA,Aaron Berger, MD Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

Assessing Risk in NMIBC: A Foundation for Therapy
ByMark D. Tyson, II, MD, MPH,Bogdana Schmidt, MD, MPH,Sam S. Chang, MD, MBA,Aaron Berger, MD Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles.